The AEMPS is aware of the advances that have been made regarding the therapeutic usefulness of cannabis. It must be remembered that the European Medicines Agency has approved several applications to develop medicines with CBD for the treatment of rare diseases, such as Dravet syndrome, perinatal asphyxia or glioma. This approval means that a pharmaceutical company can benefit from the European Union's incentives for the development of medicine, such as reduced costs and protection of competition once the medicine is put on the market.
In this sense Sera Labs, the AEMPS has granted authorization to some companies in Spain for the cultivation of cannabis for research purposes, as well as the production of derivatives of cannabis extractions. This is the case of a company that has authorization from the AEMPS to develop an experimental project called Production of flowers and leaves for the extraction of cannabinoids.
No comments:
Post a Comment